SCHEMBL24329149

SCHEMBL24329149

CC(C)CC(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 8/20 0.41
SIRT1 Q96EB6 7/20 0.41
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
SIRT3 Q9NTG7 3/20 0.39
NPY1R P25929 2/20 0.39
NPY4R P50391 2/20 0.39
NPY5R Q15761 2/20 0.39
NPY2R P49146 1/20 0.39
SIRT5 Q9NXA8 3/20 0.38
C3AR1 Q16581 1/20 0.38
ADAM10 O14672 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
MMP14 P50281 1/20 0.38
ADAM8 P78325 1/20 0.38
ADAM17 P78536 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22810892 0.89 SIRT2 (0.41) SIRT2SIRT1SIRT3SIRT5C3AR1
SCHEMBL20043710 0.88 SIRT2 (0.46) SIRT2SIRT1ITGB3ITGA2BSIRT3
SCHEMBL17683439 0.87 SIRT2 (0.45) SIRT2SIRT1ITGB3ITGA2BSIRT3
SCHEMBL23347054 0.87 SIRT2 (0.45) SIRT2SIRT1ITGB3ITGA2BSIRT3
SCHEMBL19633304 0.87 SPHK1 (0.41) SIRT2SIRT1SIRT3SIRT5C3AR1
SCHEMBL21883411 0.86 SIRT2 (0.39) SIRT2SIRT1SIRT3NPY1RNPY4R
SCHEMBL23189264 0.86 ITGB3 (0.42) SIRT2SIRT1ITGB3ITGA2BNPY1R
SCHEMBL19681568 0.86 ITGB3 (0.42) SIRT2SIRT1ITGB3ITGA2BNPY1R
SCHEMBL21205432 0.86 SIRT2 (0.48) SIRT2SIRT1SIRT3SIRT5
SCHEMBL18431308 0.85 FURIN (0.41) SIRT2SIRT1SIRT3SIRT5ADAM10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697690-B2 Site-specific glycoengineering of targeting moieties GENZYME CORPORATION (US) 2023-07-11 US disclosed
US-20220119547-A1 SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES GENZYME CORPORATION 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119547-A1 SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES CD2BP2, CD74, ENGASE SIRT2 4451/4885SIRT1 4420/4885ITGB3 402/4885
US-11697690-B2 Site-specific glycoengineering of targeting moieties CD2BP2, CD74, ENGASE SIRT2 4451/4885SIRT1 4420/4885ITGB3 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.